Abstract
GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted from endocrine cells in the intestinal mucosa in response to meals. The major effects of GLP-1 are to increase glucose-induced insulin secretion and reduce glucagon release, but GLP-1 also inhibits gastric emptying rate and reduces appetite and bodyweight in obese subjects. In vivo studies using animal models of type 2 diabetes and in vitro studies using human islet cells have suggested that GLP-1 or GLP-1 analogues are also able to increase ß-cell mass, but in animal models of type 1 diabetes, there is much less evidence for a ß-cell preserving effect. This review summarizes the present knowledge of GLP-1 and its analogues regarding its role as a possible treatment in patients with type 1 diabetes. The studies that address the effect of GLP-1 and GLP-1 analogues on ß-cell mass in both type 2 and type 1 diabetes, as well as the potential of GLP-1 as an adjuvant therapy in islet cell transplantation, will be reviewed. Suggestions for future studies of GLP-1 treatment in type 1 diabetes may include early treatment in order to preserve ß-cell mass and prolong the remission period, but should also take a potential insulin sparing effect and changes in the risk of hypoglycemia into account.
Keywords: Type 1 diabetes, GLP-1, Glucagon, ß-cell mass, Residual insulin secretion, Glycemic control
Current Diabetes Reviews
Title: Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Volume: 5 Issue: 4
Author(s): Urd Kielgast, Jens J. Holst and Sten Madsbad
Affiliation:
Keywords: Type 1 diabetes, GLP-1, Glucagon, ß-cell mass, Residual insulin secretion, Glycemic control
Abstract: GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted from endocrine cells in the intestinal mucosa in response to meals. The major effects of GLP-1 are to increase glucose-induced insulin secretion and reduce glucagon release, but GLP-1 also inhibits gastric emptying rate and reduces appetite and bodyweight in obese subjects. In vivo studies using animal models of type 2 diabetes and in vitro studies using human islet cells have suggested that GLP-1 or GLP-1 analogues are also able to increase ß-cell mass, but in animal models of type 1 diabetes, there is much less evidence for a ß-cell preserving effect. This review summarizes the present knowledge of GLP-1 and its analogues regarding its role as a possible treatment in patients with type 1 diabetes. The studies that address the effect of GLP-1 and GLP-1 analogues on ß-cell mass in both type 2 and type 1 diabetes, as well as the potential of GLP-1 as an adjuvant therapy in islet cell transplantation, will be reviewed. Suggestions for future studies of GLP-1 treatment in type 1 diabetes may include early treatment in order to preserve ß-cell mass and prolong the remission period, but should also take a potential insulin sparing effect and changes in the risk of hypoglycemia into account.
Export Options
About this article
Cite this article as:
Kielgast Urd, Holst J. Jens and Madsbad Sten, Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists, Current Diabetes Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339909789804413
DOI https://dx.doi.org/10.2174/157339909789804413 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Azathioprine in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued) Angiogenesis and Blood-Brain Barrier Permeability in Vascular Remodeling after Stroke
Current Neuropharmacology Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Chest Pain in Children
Current Pediatric Reviews Hypertensive Pharmacogenomics in African Americans
Current Pharmacogenomics Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research The Next Step in Voice Assessment: High-Speed Digital Endoscopy and Objective Evaluation
Current Bioinformatics Pharmacological Implications of MMP-9 Inhibition by ACE Inhibitors
Current Medicinal Chemistry Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Genetics and Therapies for GM2 Gangliosidosis
Current Gene Therapy Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews